Hypothesis

Age‑related loss of Clostridium sporogenes‑derived indole‑3‑propionic acid (IPA) weakens intestinal PXR activity, allowing endotoxin to leak into circulation and suppress astrocytic aquaporin‑4 (AQP4) polarization, which is required for efficient glymphatic flow during sleep. Restoring intestinal IPA‑PXR signaling rescues glymphatic waste clearance independently of neuronal PXR.

Mechanistic Rationale

• IPA produced by C. sporogenes activates intestinal PXR, upregulating tight‑junction proteins (ZO‑1, occludin, claudin‑1/4) and suppressing TLR4/NF‑κB via ACBP [1].
• Aging reduces C. sporogenes abundance and circulating IPA [2], increasing bacterial LPS translocation [3].
• Systemic LPS activates peripheral and central TLR4/NF‑κB pathways, elevating TNF‑α, IL‑6 and IL‑1β, which drive astrocytic reactivity and diminish AQP4 membrane polarization at perivascular endfeet—a prerequisite for glymphatic influx/efflux [4].
• While IPA can cross the blood‑brain barrier and activate neuronal PXR to limit amyloid‑beta and neuroinflammation [4], the glymphatic system depends chiefly on astrocytic AQP4 function, not neuronal PXR.
• Therefore, intestinal barrier integrity, modulated by IPA‑PXR, sets a systemic inflammatory tone that directly gates the brain’s nightly waste‑clearance capacity.

Testable Predictions

1. Aged mice with intestinal‑specific PXR knockout (IEC‑Pxr^−/−) will show elevated serum LPS, reduced perivascular AQP4 polarization, and impaired sleep‑dependent CSF tracer clearance compared with wild‑type controls, despite normal neuronal PXR.
2. Chronic oral IPA supplementation in IEC‑Pxr^−/− mice will normalize serum LPS, restore AQP4 polarity, and rescue glymphatic clearance without altering neuronal PXR activity.
3. Administering a TLR4 antagonist (e.g., TAK‑242) to aged IEC‑Pxr^−/− mice will ameliorate AQP4 mislocalization and glymphatic dysfunction, indicating that endotoxin‑driven inflammation mediates the effect.
4. Germ‑free mice colonized with a C. sporogenes strain deficient in IPA synthesis will phenocopy the glymphatic defect, whereas colonization with an IPA‑producing strain will prevent it.

Experimental Design

• Use IEC‑Pxr^−/− and control mice (young 3 mo, aged 18 mo).
• Measure serum LPS (LAL assay), cytokine panels, and intestinal permeability (FITC‑dextran).
• Quantify perivascular AQP4 localization by immunohistochemistry and western blot of polarized vs total AQP4.
• Assess glymphatic function via intrathecal injection of fluorescent CSF tracer (e.g., Alexa‑647‑BSA) and imaging of tracer clearance during natural sleep vs sleep deprivation.
• Intervention groups receive IPA (10 mg/kg/day oral) or vehicle; additional groups receive TLR4 antagonist.
• Statistical analysis: two‑way ANOVA (genotype × treatment) with post‑hoc Tukey; significance set at p<0.05.

If intestinal IPA‑PXR signaling proves necessary and sufficient for sleep‑dependent glymphatic clearance, this hypothesis shifts the focus from passive waste removal to an active gut‑brain gatekeeper that determines which neural networks survive the nightly edit.